11
Participants
Start Date
June 23, 2016
Primary Completion Date
May 13, 2021
Study Completion Date
March 31, 2036
Autologous Hematopoietic Stem Cell Transplantation
Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells
Carmustine
300 mg/m2 on Day -6, as part of BEAM and R-BEAM regimens.
Cytarabine
100 mg/m2 BID on Days -5 through -2, as part of BEAM and R-BEAM regimens.
Etoposide
VP-16: 100 mg/m2 BID on Days -5 through -2, as part of BEAM and R-BEAM regimens.
Laboratory Biomarker Analysis
Correlative studies
Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells
Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells
Melphalan
140 mg/m2 on Day -1, as part of BEAM and R-BEAM regimens.
Peripheral Blood Stem Cell Transplantation
Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells
Memorial Sloan Kettering Cancer Center, New York
UC San Diego Moores Cancer Center, La Jolla
UCSF Medical Center-Parnassus, San Francisco
University of California Davis Comprehensive Cancer Center, Sacramento
National Cancer Institute (NCI)
NIH
California Institute for Regenerative Medicine (CIRM)
OTHER
AIDS Malignancy Consortium
NETWORK